The SPIRIT v study

JACC: Cardiovascular Interventions

Volumn 4, Issue 2, 2011, Pages 168-175

  Grube, Eberhard ^a   Chevalier, Bernard ^b   Smits, Peter ^c   Davk, Vladimir ^d   Patel, Tejas M ^e   Mullasari, Ajit S ^f   Whrle, Jochen ^g   Stuteville, Marrianne ^h   Dorange, Ccile ^h   Kaul, Upendra ⁱ  

^a UNIVERSITY HOSPITAL BONN   (Germany)

^b INSTITUT HOSPITALIER JACQUES CARTIER   (France)

^c Maasstad Hospital Rotterdam   (Netherlands)

^d UNIVERSITY HEALTH NETWORK   (Canada)

^e Krishna Heart Institute   (India)

^f MADRAS MEDICAL MISSION HOSPITAL   (India)

^g UNIVERSITY OF ULM   (Germany)

^h ABBOTT VASCULAR   (United States)

ⁱ ESCORTS HEART INSTITUTE AND RESEARCH CENTRE   (India)

Author keywords

drug eluting stent (DES); everolimus; percutaneous coronary intervention (PCI); stent

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; EVEROLIMUS;

ADULT; ARTERY DIAMETER; ARTICLE; ASIA; CANADA; CLINICAL EVALUATION; CORONARY ARTERY DISEASE; CORONARY ARTERY RECANALIZATION; CORONARY STENT; DRUG ELUTING STENT; EUROPE; FEMALE; HEART DEATH; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; SOUTH AFRICA; STENT THROMBOSIS;

AGED; ANGIOPLASTY, BALLOON, CORONARY; ASIA; CANADA; CARDIOVASCULAR AGENTS; CORONARY ARTERY DISEASE; DISEASE-FREE SURVIVAL; DRUG-ELUTING STENTS; EUROPE; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PRODUCT SURVEILLANCE, POSTMARKETING; PROSPECTIVE STUDIES; PROSTHESIS DESIGN; REGISTRIES; RISK ASSESSMENT; RISK FACTORS; SIROLIMUS; SOUTH AFRICA; THROMBOSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 79951969396     PISSN: 19368798     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcin.2010.11.006     Document Type: Article

References (15)

1. M.-C. Morice XIENCE V SPIRIT WOMEN clinical trial: characterization of the female population undergoing stent implantation Womens Health (Lond Engl) 4 2008 439 443
2. K. Tsuchida, J. Piek, and F. Neumann One-year results of a durable polymer everolimus-eluting stent in de novo coronary narrowings (The SPIRIT FIRST Trial) EuroIntervention 1 2005 266 272
3. M. Beijk, F. Neumann, and M. Wiemer Two-year results of a durable polymer everolimus-eluting stent in de novo coronary artery stenosis (The SPIRIT FIRST Trial) EuroIntervention 3 2007 206 212
4. P. Serruys, P. Ruygrok, and J. Neuzner A randomized comparison of an everolimus-eluting coronary stent with a paclitaxel-eluting coronary stent: the SPIRIT II trial EuroIntervention 2 2006 286 294
5. G.W. Stone, M. Midei, and W. Newman Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial JAMA 299 2008 1903 1913 (Pubitemid 351574920)
6. D.E. Cutlip, S. Windecker, and R. Mehran Clinical end points in coronary stent trials: a case for standardized definitions Circulation 115 2007 2344 2351 (Pubitemid 46685903)
7. P. Ruygrok, M. Desaga, and F.V.D. Branden One year clinical follow-up of the XIENCE V everolimus-eluting stent system in the treatment of patients with de novo native coronary artery lesions: the SPIRIT II study EuroIntervention 3 2007 315 320
8. B. Claesen, M. Beijk, and V. Legrand Two-year clinical, angiographic, and intravascular ultrasound follow-up of the XIENCE V everolimus-eluting stent in the treatment of patients with de novo native coronary artery lesions: the SPIRIT II trial Circ Cardiovasc Interv 2 2009 339 347
9. G.W. Stone, M. Midei, and W. Newman Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the Clinical Evaluation of the Xience V everolimus Eluting Coronary Stent System in the Treatment of patients with de novo Native Coronary Artery Lesions (SPIRIT) III Trial Circulation 119 2009 680 686
10. G. Stone, A. Rizvi, and W. Newman Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease N Engl J Med 362 2010 1663 1674
11. Y. Onuma, N. Kukreja, and N. Piazza The everolimus-eluting stent in real-world patients: 6-month follow-up of the X-SEARCH (Xience V Stent Evaluated at Rotterdam Cardiac Hospital) Registry J Am Coll Cardiol 54 2009 269 276
12. E. Kedhi, K.S. Joesoef, and E. McFadden Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial Lancet 375 2010 201 209
13. P. Urban, A.H. Gershlick, and G. Guagliumi Safety of coronary sirolimus-eluting stents in daily clinical practice: one-year follow-up of the e-Cypher registry Circulation 113 2006 1434 1441 (Pubitemid 43739440)
14. A. Abizaid, C. Chan, and Y.-T. Lim Twelve-month outcomes with a paclitaxel-eluting stent transitioning from controlled trials to clinical practice (the WISDOM Registry) Am J Cardiol 98 2006 1028 1032 (Pubitemid 44486137)
15. J. Lasala, D. Cox, and S. Lewis Expanded use of the TAXUS Express stent: two-year safety insights from the 7,500 patient ARRIVE Registry programme EuroIntervention 5 2009 67 77